Results 81 to 90 of about 6,976 (207)
Health Science Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background and Aim Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients ...
Arash Akbarzadeh +7 more
wiley +1 more source
Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models
Journal of Medical Virology, Volume 98, Issue 10, October 2026.ABSTRACT Over the past two decades, coronaviruses have caused three major public health crises, including the epidemics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2. Following the outbreak of SARS‐CoV‐2, several antiviral drugs have been approved for the treatment of COVID‐19.
Cuiling Zhang +9 more
wiley +1 more source
MedComm, Volume 7, Issue 9, September 2026.SARS‐CoV‐2 infection causes COVID‐19 and stimulates immune cells, such as dendritic cells, monocytes, and macrophages, to increase levels of many cytokines. Ursodeoxycholic acid (UDCA) inhibits farnesoid X receptor (FXR), resulting in a decrease in the activity of angiotensin‐converting enzyme 2 (ACE2), the main receptor on the membrane for SARS‐CoV‐2.
Zhaowei Tong +8 more
wiley +1 more source
Elektroenzymatische CO2‐Fixierung
Angewandte Chemie, Volume 138, Issue 28, 6 July 2026.Die elektroenzymatische CO2‐Fixierung ermöglicht eine energieeffiziente, hochselektive Synthese komplexer Moleküle. Um ihr volles Potenzial auszuschöpfen, ist ein grundlegendes Verständnis von elektrodengekoppelten Reduktasen und Carboxylasen erforderlich.
Leonardo Castañeda‐Losada +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman +9 more
wiley +1 more source
Fact sheet for Molnupiravir. Portuguese
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029C12292021 PORTUGUESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Clinical and Translational Science, 2022 The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the ...
Raymond K. Hau +2 more
doaj +1 more source
Fact sheet for Molnupiravir. Chinese
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029C12292021 SIMPLIFIED CHINESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
DFT and Molecular Docking Studies of an Antiviral Drug: Molnupiravir
, 2023 810-812This paper presents computational analysis of molnupiravir, the first orally administered antiviral drug approved by MHRA for the cure of COVID-19.
Mishra, Abhinav +2 more
core +1 more source
ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants
Journal of Medical Virology, Volume 98, Issue 7, July 2026.ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández +5 more
wiley +1 more source